Your browser doesn't support javascript.
loading
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study.
Li, Yinjuan; Qi, Lu; Bai, Haihong; Sun, Chunyun; Xu, Shuping; Wang, Yu; Han, Chunyu; Li, Yan; Liu, Long; Cheng, Xiaoqiang; Liu, Ju; Lei, Chunpu; Tong, Yuanxu; Sun, Mingli; Yan, Lixin; Chen, Weiqiu; Liu, Xisheng; Liu, Qing; Xie, Liangzhi; Wang, Xinghe.
Afiliação
  • Li Y; Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Qi L; Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Bai H; Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Sun C; Sinocelltech Ltd., Beijing, China.
  • Xu S; Beijing Engineering Research Center of Protein and Antibody, Beijing, China.
  • Wang Y; Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Han C; Sinocelltech Ltd., Beijing, China.
  • Li Y; Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Liu L; Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Cheng X; Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Liu J; Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Lei C; Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Tong Y; Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Sun M; Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Yan L; Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Chen W; Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Liu X; Sinocelltech Ltd., Beijing, China.
  • Liu Q; Sinocelltech Ltd., Beijing, China.
  • Xie L; Sinocelltech Ltd., Beijing, China.
  • Wang X; Sinocelltech Ltd., Beijing, China.
Antimicrob Agents Chemother ; 65(11): e0106321, 2021 10 18.
Article em En | MEDLINE | ID: mdl-34491805
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article